BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor

Homologous Recombination Deficiency (HRD) is a frequent feature of high-grade epithelial ovarian carcinoma (EOC), associated with sensitivity to PARP-inhibitors (PARPi). The best characterized causes of HRD in EOCs are germline or somatic mutations in and genes. Although promoter methylation is a we...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences Vol. 21; no. 24; p. 9708
Main Authors: Sahnane, Nora, Carnevali, Ileana, Formenti, Giorgio, Casarin, Jvan, Facchi, Sofia, Bombelli, Raffaella, Di Lauro, Eleonora, Memoli, Domenico, Salvati, Annamaria, Rizzo, Francesca, Sessa, Fausto, Tibiletti, Maria Grazia
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 19-12-2020
MDPI
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Homologous Recombination Deficiency (HRD) is a frequent feature of high-grade epithelial ovarian carcinoma (EOC), associated with sensitivity to PARP-inhibitors (PARPi). The best characterized causes of HRD in EOCs are germline or somatic mutations in and genes. Although promoter methylation is a well-known mechanism of gene transcriptional repression, few data have been published about gene methylation in EOCs. In this retrospective study, we quantitatively analyzed by pyrosequencing a selected series of 90 formalin-fixed (FFPE) primary EOCs without germline mutations. We identified 20/88 (22.7%) EOCs showing promoter methylation, including 17/88 (19.3%) in and 4/86 (4.6%) in promoters, one of which showing concomitant methylation. Mean methylation levels were 49.6% and 45.8% for and respectively, with methylation levels ≥50% in 10/20 methylated EOCs. Constitutive methylation was excluded by testing blood-derived DNA. In conclusion, pyrosequencing methylation analysis of genes is a robust, quantitative and sensitive assay applicable to FFPE samples. Remarkably, a considerable subset of germline -negative EOCs showed somatic methylation and, likely, HRD. A subpopulation of women with methylation, even without mutations, could potentially benefit from PARP-inhibitors; further clinical studies are needed to clarify the predictive role of somatic methylation of PARP-therapy response.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms21249708